<H1>
To lead NIH, Trump taps Stanford academic and pandemic response critic Jay Bhattacharya
</H1> |
<H1>
The Biden administration wants Medicare and Medicaid to cover GLP-1s. Will the Trump White House allow it?
</H1> |
<H1>
Sarepta licenses Arrowhead's RNA-based rare disease pipeline, promising big biobucks
</H1> |
<H1> Lawmakers are poking holes in pharma's favorite new way to market medicines </H1> |
<H1> A rare neurological disease is Sage’s last, best hope after failures in depression </H1> |
<H1> Yorvipath’s approval showcases biopharma’s interest in rare endocrine disorder </H1> |
<H1> Biotech industry worries over potential for RFK Jr. ally as FDA pick </H1> |
<H1> How the world's biggest pharma and biotech companies paid their typical worker in 2023 </H1> |
<H1> In biotech's uneven recovery, 50 startups raised megarounds in first half of 2024 </H1> |
<H1> Biopharma leaders charting a path for the industry's LGBTQ+ community </H1> |
<H1> Peter Marks single-handedly approved Sarepta’s gene therapy — what does that mean for everyone else? </H1> |
<H1> Bristol Myers reveals more job cuts in New Jersey </H1> |
<H1> Minnesota 340B revenue driven by hospitals and high-priced drugs, first state report says </H1> |
<H1> Merck halts Phase 3 trial with PAH drug Winrevair following positive interim data </H1> |
<H1> RFK Jr. and Elon Musk want to ban pharma ads. They wouldn't be the first to try </H1> |
<H1> FDA says Merz's social media promotion with Nate Berkus is 'misleading' </H1> |
<H1> Valneva and Pfizer eye 2027 launch for partnered Lyme disease vaccine </H1> |
<H1> Trump team asked Warp Speed leader to head NIH, may seek more traditional pick for role </H1> |
<H1> FDA adcomm raises risk questions on AstraZeneca’s Andexxa </H1> |
<H1> Jazz wins approval for bispecific in biliary tract cancer </H1> |
<H1> Agilent reveals plans to remodel operations as annual revenue dips </H1> |
<H1> At Jefferies, all that manufacturers want to talk about is GLP-1s </H1> |
<H1> Samsung Bio's new $668M client; Sanofi expands a factory in France </H1> |
<H3> top stories </H3> |
<H3> Latest </H3> |
<H3>
Updated: Amgen obesity shot shows 20% weight loss, but dosing questions hang over readout
</H3> |
<H3>
Axsome moves toward NDA filing for narcolepsy drug following positive Phase 3 data
</H3> |
<H3>
Food allergy biotech Alladapt closes after Phase 3 talks with FDA
</H3> |
<H3>
Soleno’s rare pediatric disease drug faces PDUFA delay by three months
</H3> |
<H3>
For CDC, Trump picks Dave Weldon, a former congressman who pushed for vaccine injury claims
</H3> |
<H3>
Trump taps Johns Hopkins researcher Marty Makary to lead the FDA; also names CDC, surgeon general picks
</H3> |
<H3>
Lexicon ends commercial work to focus on R&D
</H3> |
<H3>
Why Morgan Health is backing an autism care company
</H3> |
<H3>
ADC biotech Adcendo nabs $135M Series B as it enters the clinic
</H3> |
<H3>
Microsoft-backed Enveda raises $130M for drugs in I&I, obesity and other areas
</H3> |
<H3>
Gilead buys experimental HIV vaccines from a small Barcelona biotech
</H3> |
<H3>
Venrock adds $500M to healthcare investing strategy after outlining 10th fund in January
</H3> |
<H3>
Carolyn Bertozzi’s latest biotech debuts with $30M seed round and a sugary spin on immunotherapy
</H3> |
<H3>
Updated: Roche buys out CAR-T partner Poseida for $1B upfront
</H3> |
<H3>
Cradle Bio raises $73M Series B to sell pharma its protein-making AI software
</H3> |
<H3>
Halozyme withdraws Evotec acquisition proposal after biotech is 'unwilling to engage'
</H3> |
<H3>
In FocusSee all
</H3> |
<H3>
Endpoints Standouts
</H3> |
<H3> Peer review
See all </H3> |
<H3> Lilly's board undergoes more changes; Merck strategy chief joins Roger Perlmutter at Eikon </H3> |
<H3> ALX Oncology hires Genentech, Mirati vet as CMO; After Carmot, Heather Turner has three new roles on tap </H3> |
<H3> Legend names a president of Carvykti; Novo Nordisk's top North America exec is stepping down </H3> |
<H3> Biogen brings in medical chief as CFO plans retirement; MacroGenics CEO announces departure </H3> |
<H3> Chinook alums reunite following exit to Novartis; The first board appointment for Recursion’s Chris Gibson </H3> |
<H3>
Pharma channel feed </H3> |
<H3>
AstraZeneca’s Truqap edges closer to prostate cancer label expansion with Phase 3 win
</H3> |
<H3>
FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam
</H3> |
<H3>
Sanofi introduces new 340B payment model — report
</H3> |
<H3>
Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders
</H3> |
<H3>
Senate Judiciary Committee advances patent bill with new protections for pharma challenges
</H3> |
<H3>
Marketing channel feed </H3> |
<H3>
UK watchdog criticizes Moderna for Covid-19 trial's use of WhatsApp to dangle payments to children
</H3> |
<H3>
FDA criticizes AbbVie's 'misleading' ad with Serena Williams
</H3> |
<H3>
Updated: Madrigal finally reveals first wave of sales for MASH drug Rezdiffra
</H3> |
<H3>
RSV market pressure leads to slower launch for Moderna's vaccine
</H3> |
<H3>
Verona inks financing deal worth up to $650M ahead of COPD decision
</H3> |
<H3>
FDA+ channel feed </H3> |
<H3>
FDA updates label of 33-year-old cancer drug with new dose and warning
</H3> |
<H3>
When generative AI meets the FDA: First digital health adcomm kicks off discussion
</H3> |
<H3>
GSK plots regulatory filings for PBC itch after positive Phase 3 readout
</H3> |
<H3>
FDA rejects Astellas’ effort to support longer use of eye drug Izervay
</H3> |
<H3>
Ahead of adcomm, FDA raises safety questions for AstraZeneca’s reversal agent for life-threatening bleeds
</H3> |
<H3>
Manufacturing channel feed </H3> |
<H3>
Chinese drugmaker receives FDA warning letter after management hindered inspection
</H3> |
<H3>
Evotec gains on Halozyme's takeover proposal
</H3> |
<H3>
European Commission seeks biopharma feedback on Novo-Catalent deal — report
</H3> |
<H3>
Lonza expands bioconjugates factory; WuXi Bio adds capacity in Germany
</H3> |
<H3>
Novo Nordisk to phase out its production of human insulin pens globally
</H3> |
<H3> Latest </H3> |
<H3> Channels </H3> |
<H3> More </H3> |
<H3> Work in biotech </H3> |
<H3>
Log in to your account
</H3> |
<H3>
email
</H3> |
<H3>
password
</H3> |
<H3>
request magic link
</H3> |
<H3>
email
</H3> |
<H3>
reset password
</H3> |
<H3>
email
</H3> |
<H3>
</H3> |
<H3>
Newsletter Interests
</H3> |
Social
Social Data
Cost and overhead previously rendered this semi-public form of communication unfeasible.
But advances in social networking technology from 2004-2010 has made broader concepts of sharing possible.